Engineered NK cell therapy for relapsed blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new immune cell therapy (engineered NK cells) for people with certain blood cancers like AML, MDS, or CMML that have not responded to standard treatments. The therapy aims to help your immune system attack cancer cells, and is given after a short course of chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your cancer (AML, high-risk MDS, or CMML) must have come back or not gotten better after treatment.
- Your cancer cells must have a protein called CD70 on at least 10% of them.
- You must be in generally good health (able to do most daily activities).
- Your liver, heart, kidneys, and lungs must work well enough for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
This study tests a new treatment using natural killer (NK) cells that are specially created in the lab to find and attack cancer cells that have a protein called CD5 on their surface. The treatment is given along with chemotherapy to help the NK cells work better. It may be an option for people with certain types of T-cell lymphoma or leukemia that have not responded to other treatments.
This trial tests a new type of immune cell therapy using cord blood cells that are grown to attack cancer cells. It is for people with certain blood cancers (lymphoma or acute lymphoblastic leukemia) that have come back or not responded to standard treatments.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
Hear when a new Myeloid Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.